Elma S. Hawkins
Founder chez Redpin Therapeutics, Inc.
Profil
Elma S.
Hawkins is the founder of Redpin Therapeutics, Inc. (founded in 2017) where she holds the title of President, Chief Executive Officer & Director.
She is currently the Chairman at EpiBone, Inc. Dr. Hawkins previously served as the President & Chief Executive Officer at Advanced Viral Research Corp.
She also held the position of Director at Iovance Biotherapeutics, Inc. from 2016 to 2016.
Dr. Hawkins has an MBA from Boston University and a doctorate from The University of Alabama.
Postes actifs de Elma S. Hawkins
| Sociétés | Poste | Début |
|---|---|---|
EpiBone, Inc.
 EpiBone, Inc. Medical SpecialtiesHealth Technology Epibone, Inc. develops bone reconstruction solutions. Its technology utilizes a scan of the patient?s bone defect and the patient?s own stem cells to construct and cultivate an autologous-like bone graft that provides defect repair, and improves bone formation and regeneration. The company was founded by Nina Tandon, Gordana Vunjak-Novakovic, Sarindr Bhumiratana, Sidney Eisig, and Elisa Cimetta and is headquartered in Brooklyn, NY. | Chairman | - |
Redpin Therapeutics, Inc.
 Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Founder | 01/01/2017 |
Anciens postes connus de Elma S. Hawkins
| Sociétés | Poste | Fin |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Chief Executive Officer | 01/06/2016 |
Advanced Viral Research Corp.
 Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | President | 18/02/2006 |
Formation de Elma S. Hawkins
| Boston University | Masters Business Admin |
| The University of Alabama | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
EpiBone, Inc.
EpiBone, Inc. Medical SpecialtiesHealth Technology Epibone, Inc. develops bone reconstruction solutions. Its technology utilizes a scan of the patient?s bone defect and the patient?s own stem cells to construct and cultivate an autologous-like bone graft that provides defect repair, and improves bone formation and regeneration. The company was founded by Nina Tandon, Gordana Vunjak-Novakovic, Sarindr Bhumiratana, Sidney Eisig, and Elisa Cimetta and is headquartered in Brooklyn, NY. | Health Technology |
Redpin Therapeutics, Inc.
Redpin Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY. | Commercial Services |
